Találati lista | Tudóstér

001-es BibID:	BIBFORM117737
035-os BibID:	(WoS)001134150900001 (Scopus)85181231963
Első szerző:	Azzam, Ahmed
Cím:	HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs) : a Systematic Review and Meta-Analysis / Ahmed Azzam, Heba Khaled, Basem Osama Ashry, Sarah Mohamed Hussein, Manar Osama, Ameer Ahmed, Omar Yousef, Anees Hjazeen, Ahmed A. Allam, Gellan Alaa Mohamed Kamel
Dátum:	2024
ISSN:	1523-3847 1534-3146
Megjegyzések:	Purpose of Review: Bruton tyrosine kinase inhibitors (BTKIs) are immunosuppressive cancer therapies approved for the treatment of various mature B-cell malignancies. Hepatitis B virus reactivation (HBVr) is a known complication in patients with chronic or past HBV infection undergoing immunosuppressive chemotherapy. The present work aims to establish the correlation between HBVr and patients receiving BTKIs. Recent Findings: This review included 18 studies. The overall incidence of HBVr was found to be 6.6% in patients with past HBV infections who received ibrutinib. Fourteen cases of HBVr were associated with ibrutinib (two occult hepatitis B infections and twelve past HBV infections). One case of HBV past infection was associated with zanubrutinib, and three cases were recorded for acalabrutinib (one chronic HBV and two past HBV). Most incidents occurred in males older than 60 years within the first year after initiating BTKIs. Three reported cases documented HBVr after discontinuing ibrutinib and zanubrutinib. Two deaths caused by HBVr in patients with past HBV infections were recorded (one for each of acalabrutinib and ibrutinib). Remarkably, HBV antiviral treatment normalized liver functions and eliminated serum HBV in most cases. It was reported that false negativity of HBsAg following reactivation occurred in two cases: one case was attributed to HBsAg escape mutations, and the other to the hook effect. Summary: Our findings show that HBVr risk is intermediate in patients with past HBV infections who receive ibrutinib. Universal anti-HBV prophylaxis before initiating ibrutinib may be an option.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk Bruton tyrosine kinase inhibitors BTKIs Ibrutinib Zanubrutinib Acalabrutinib Hepatitis B virus reactivation HBVr Systematic review Meta-analysis
Megjelenés:	Current Infectious Disease Reports. - [Epub ahead of print] (2024). -
További szerzők:	Khaled, Heba Ashry, Basem Osama Hussein, Sarah Mohamed Osama, Manar Ahmed, Ameer Yousef, Omar Ahmed Elsayed Hjazeen, Anees Allam, Ahmed A. Kamel, Gellan Alaa Mohamed
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: